Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, ...

EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible ...

and supported by the Coalition for Epidemic Preparedness Innovations (CEPI), to advance the fight against the deadly haemorrhagic Lassa Fever and accelerate the development and future equitable ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free ...

Bio Usawa, a private biotech company focused on boosting drug access in Africa, inked a deal with cleanroom and laboratory ...

The Trump administration Department of Health and Human Services has canceled a $766 million contract with Moderna to ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

Are reopening states jumping the gun? How precise is the Hopkins map? Dr. Tom Inglesby, of the Hopkins Bloomberg School of Public Health, answers USA TODAY.